Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct 3:13:1309-1316.
doi: 10.2147/TCRM.S144659. eCollection 2017.

Decreased frequency of adenoidectomy by a 12-week nasal budesonide treatment

Haiyu Hong #  1 , Fenghong Chen #  2 , Xiaobin Zheng  3 , Wei Liao  1 , Zhenpeng Liao  1 , Yujie Cao  2 , Haixin He  1 , Zhe Zhu  4   5 , Yunping Fan  1
Affiliations

Decreased frequency of adenoidectomy by a 12-week nasal budesonide treatment

Haiyu Hong et al. Ther Clin Risk Manag. .

Abstract

Objective: There is little evidence on the role of topical budesonide in reducing the frequency of adenoidectomy, although it was reported that topical budesonide can effectively ameliorate the symptoms of adenoid hypertrophy (AH). This study was aimed to investigate the possibility and safety of alternatives to adenoidectomy with a 12-week treatment with nasal budesonide.

Materials and methods: One hundred patients with AH were randomized to receive either a double-blind budesonide (1 mg once daily) or placebo treatment for 2 weeks by transnasal nebulization. A further 12-week open study, budesonide spray (64 μg per nostril at bedtime) was administered to the treatment group. During the final 12 weeks of follow-up, the frequency of adenotonsillectomy, side effects, the degree of nasal obstruction, nasal discharge, and snoring were assessed.

Results: Out of the 100 total enrolled patients, 92 children with AH completed the study. After the 2-week treatment with transnasal budesonide nebulization, the symptoms of AH significantly decreased compared to the control group. Responders (n=26) who had initially improved showed significantly decreased symptoms of AH, and the frequency of adenotonsillectomy during the follow-up (14 and 26 weeks) was compared with that of the control group and non-responders (n=21) who did not respond to the initial 2-week budesonide therapy. The 12-week nasal budesonide treatment did not suppress the growth rate of children's height or cause other side effects.

Conclusion: AH children who had improved after an initial 2-week budesonide therapy can achieve clinical improvements and decreased frequency of adenoidectomy following the therapy with a 12-week treatment with nasal budesonide.

Keywords: adenoid hypertrophy; adenoidectomy; budesonide; frequency; treatment.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Flow diagram of this study. Abbreviations: AH, adenoid hypertrophy; w, weeks.
Figure 2
Figure 2
Clinical improvements between groups, including nasal obstruction index (A), nasal discharge degree (B), and snoring degree (C). Notes: A P-value in green means the value was compared to the control group. A P-value in purple means the value was compared to the non-responder group.
Figure 3
Figure 3
Representative nasal endoscopic follow-ups of a responder at 0 (A), 2 (B), 14 (C), and 26 weeks (D).
Figure 4
Figure 4
Growth rates of children’s height between groups.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kaditis AG, Alonso AM, Boudewyns A, et al. Obstructive sleep disordered breathing in 2- to 18-year-old children: diagnosis and management. Eur Respir J. 2016;47:69–94. - PubMed
    1. Baugh RF, Archer SM, Mitchell RB, et al. Clinical practice guideline: tonsillectomy in children. Otolaryngol Head Neck Surg. 2011;144:S1–S30. - PubMed
    1. Brodsky L. Modern assessment of tonsils and adenoids. Pediatr Clin North Am. 1989;36:1551–1569. - PubMed
    1. Garetz SL, Mitchell RB, Parker PD, et al. Quality of life and obstructive sleep apnea symptoms after pediatric adenotonsillectomy. Pediatrics. 2015;135:e477–e486. - PMC - PubMed
    1. Zojaji R, Mirzadeh M, Mazloum FBM, Khorashadizadeh M, Sabeti HR. The effect of adenotonsillectomy on children’s quality of life. Iran J Otorhinolaryngol. 2014;26:199–205. - PMC - PubMed

LinkOut - more resources